Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbo/Taxol/Pembro Followed by Olaparib/Pembro Maintenance in Newly Diagnosed Stage III/IV Ovarian Cancer
NCT05952453Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2025
- Primary completion
- Oct 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by University of Alabama at Birmingham. Started Feb 2025; status: recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05952453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952453.